[
  {
    "ts": null,
    "headline": "How Recent Shifts Are Changing the Narrative for Moderna Stock",
    "summary": "Moderna's narrative is shifting as analysts modestly trim their fair value from $37.32 to $35.78 per share and nudge the discount rate from 7.13% to 7.13%, reflecting a slightly higher required return amid ongoing debates around execution risk and cash sustainability. Long term revenue growth expectations have also eased from 10.31% to 10.22%, as models balance stronger liquidity and oncology optionality against litigation and pipeline uncertainties. Stay tuned to see how you can track these...",
    "url": "https://finnhub.io/api/news?id=48b51eebb8a4bf911b5285274cdc8572ed856f7c382c214a61b27fd19e01701b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765105808,
      "headline": "How Recent Shifts Are Changing the Narrative for Moderna Stock",
      "id": 137726791,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna's narrative is shifting as analysts modestly trim their fair value from $37.32 to $35.78 per share and nudge the discount rate from 7.13% to 7.13%, reflecting a slightly higher required return amid ongoing debates around execution risk and cash sustainability. Long term revenue growth expectations have also eased from 10.31% to 10.22%, as models balance stronger liquidity and oncology optionality against litigation and pipeline uncertainties. Stay tuned to see how you can track these...",
      "url": "https://finnhub.io/api/news?id=48b51eebb8a4bf911b5285274cdc8572ed856f7c382c214a61b27fd19e01701b"
    }
  }
]